Opinion|Videos|December 9, 2025
Examining a Novel FDA-approved Therapy in Desmoid Tumors
FDA approval of Nirogacistat for desmoid tumors highlights improved survival rates, quality of life, and manageable side effects for patients.
Advertisement
Episodes in this series
Panelists discuss the questions below in this video.
- What was the key
data that led to the FDA approval of nirogacestat in patients with desmoid tumors? How does its mechanism of action differ from other therapies? Can you describe thedata from the long-term study of nirogacestat? Why is this study valuable to clinicians? From your clinical experience, how has patient satisfaction been with nirogacestat? What has long-termdata demonstrated? What was found in studies that evaluated nirogacestat inpatient-reported outcomes andpain control? Ovarian toxicity was seen in the clinical trials in women treated with nirogacestat. What was theoutcome in these patients and is any intervention necessary?
Advertisement
Related to this article
Adults with moderately to severely active Crohn disease can now start risankizumab with an on-body injector at home.
For all the advances in breast cancer, there remains unmet need for patients whose cancer progresses after treatment with antibody-drug conjugates (ADCs). In the final week of Breast Cancer Awareness Month, AJMC® looks at an investigational vaccine approach that could come after ADCs, offering patients a low-toxicity regimen.
Hiddo Heerspink, PhD, discusses finerenone data in type 1 diabetes, FSGS and IgA nephropathy, and open questions on sequencing CKD therapies.
Advertisement
Advertisement
Trending on AJMC
1
IDWeek Studies Tie RSV, Flu, and COVID-19 to Harm After Acute Illness
2
Preparing for Hepatitis B Functional Cure: Jordan Feld, MD, MPH
3
Povetacicept Cuts Proteinuria by 52% in IgA Nephropathy at Week 36
4
Nephrologists Weigh Wins, Losses From 5 Years of Value-Based Kidney Care
5